It was learnt in the 13th Great Wall Cardiology Society held recently that the sirolimus drug-eluting stent developed and produced by Johnson & Johnson will be put into wide clinical application in China shortly; the stent will effectively prevent postoperative restenosis of intra-coronary artery stent.
Professor Gao Runlin of Beijing Fuwai Hospital said that the clinical trial on sirolimus drug-eluting stent started last year in Beijing Fuwai Hospital and People's Hospital of Guangdong province. Up to the present, 41 cases had undergone the procedure; 20 cases were followed-up for 6 months and there is as yet no restenosis occurred, nor is there any side effect or complication. The remaining 21 cases are still under follow-up. The sirolimus drug-eluting stent was already in widespread application in approximately 20 countries in Europe and Asian-Pacific regions and around 10 thousand patients were registered to accept the treatment in the world.
|
